ArticleThe American journal of bioethics : AJOB2013
Ethics of clinical science in a public health emergency: drug discovery at the bedside.
Article in The American journal of bioethics : AJOB, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Research ethics during infectious disease outbreaks: A survey of African research stakeholders using the Ebola virus disease outbreak as a case.Journal of public health in Africa · 2023Article
- The unnaturalistic fallacy: COVID-19 vaccine mandates should not discriminate against natural immunity.Journal of medical ethics · 2022Article
- Conditions of Global Health Crisis Decision-Making-An Ethical Analysis.Journal of bioethical inquiry · 2021Article
- Patients' Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation.Innovation (Cambridge (Mass.)) · 2020Article
- COVID-19 Ethics and Research.Mayo Clinic proceedings · 2020Article
- The Ebola clinical trials: a precedent for research ethics in disasters.Journal of medical ethics · 2018Article
- Critical role of ethics in clinical management and public health response to the West Africa Ebola epidemic.Risk management and healthcare policy · 2016Review
- Taking the bull by the horns: Ethical considerations in the design and implementation of an Ebola virus therapy trial.Social science & medicine (1982) · 2016Review
- Ebola: a holistic approach is required to achieve effective management and control.The Journal of allergy and clinical immunology · 2015Review
- Public health emergencies: research's friend or foe?The American journal of bioethics : AJOB · 2013Article
- Human Research Protections during Emergencies: An Integrative Review.Ethics & human researchReview
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical research under the usual regulatory constraints may be difficult or even impossible in a public health emergency. Regulators must seek to strike a good balance in granting as wide therapeutic access to new drugs as possible at the same time as gathering sound evidence of safety and effectiveness. To inform current policy, I reexamine the philosophical rationale for restricting new medicines to clinical trials, at any stage and for any population of patients (which resides in the precautionary principle), to show that its objective to protect public health, now or in the future, could soon be defeated in a pandemic. Providing wider therapeutic access and coordinating observations and natural experiments, including service delivery by cluster (wedged cluster trials), may provide such a balance. However, there are important questions of fairness to resolve before any such research can proceed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.